(NASDAQ: CNSP) Cns Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.44%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.
Cns Pharmaceuticals's earnings in 2025 is -$15,458,581.On average, 4 Wall Street analysts forecast CNSP's earnings for 2025 to be -$19,753,543, with the lowest CNSP earnings forecast at -$20,271,182, and the highest CNSP earnings forecast at -$18,949,936. On average, 4 Wall Street analysts forecast CNSP's earnings for 2026 to be -$5,966,209, with the lowest CNSP earnings forecast at -$7,770,620, and the highest CNSP earnings forecast at -$3,957,707.
In 2027, CNSP is forecast to generate -$5,368,416 in earnings, with the lowest earnings forecast at -$6,419,208 and the highest earnings forecast at -$4,174,898.